zentaris.com

ÆTERNA ZENTARIS

In Pursuit of Medical Innovations

FINANCIAL SNAPSHOT	
NASDAQ/TSX:	AEZS
SHARE PRICE:*	$1.11
MARKET CAP:*	~$133M
SHARES OUTSTANDING:	~120M

*As of April 05, 2021

Investor and Media Relations
JTC Team
833.475.8247
aezs@jtcir.com

Specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests

Where We Are Today

Investment Highlights

Macrilen™ 60 mg (macimorelin) for oral solution

Macimorelin

First and only approved oral drug indicated for diagnosis of adult growth hormone deficiency (AGHD)

FDA · European Medicines Agency

novo nordisk

United States and Canada Commercial and Development Partner

Novo Nordisk is the global leader in growth hormone deficiency therapeutic market

Consilient Health

European Commercial Partner

Consilient Health is a privately owned pharma company focused on commercializing medicines in Europe and the Middle East

Growth Opportunities

Childhood-Onset Growth Hormone Deficiency (CGHD) Testing	Macimorelin as a Therapeutic	Pipeline Expansion
Leveraging AGHD Approval and Compelling Safety Profile[1]	Working with The University of Queensland	Advancing Therapeutic and Vaccine Programs

1: Macrilen [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2018; Macimorelin summary of product characteristics (SmPC) approved by European Commission

Commercial and Development Pipeline



Macimorelin Commercial Rights

Actively seeking commercial partners in ROW

License and Assignment Agreement

- Territories: United States and Canada
- Royalties on sales
- Sales milestones
- Aeterna Zentaris controls API supply chain and provides API
- Co-development for expansion into CGHD
  - Novo Nordisk to fund 100% of budgeted Study P02 trial expenses up to €9 million
  - Potential additional expenses to be shared

License Agreement

- Territories: Europe and the United Kingdom
- Pricing and reimbursement milestones
- Royalties on sales
- Aeterna Zentaris controls supply chain and provides finished product according to supply agreement

Distribution and Commercialization Agreement
in Israel and the Palestine Authority

Owns Worldwide Rights Outside of U.S., Canada, Europe, Israel and Palestine Authority

Leveraging Clinical Success and Compelling Safety Profile

Expand Macimorelin Into CGHD Testing Through Use of Pediatric Development Plan

CGHD Clinical Development Strategy

Dose Finding Study (P01)

Positive results announced April 2020

✓

Provides Framework for Study P02

Pivotal Study (P02): Test Efficacy and Safety

Expected commencement date

Early Q2 2021

- **Co-Development with Novo Nordisk (NN)**
- **Aeterna Zentaris to be the responsible Sponsor overseeing the study**
- **NN to fund 100% of budgeted Study P02 trial expenses up to €9 million**
- **Potential additional expenses to be shared**

Expected Value Driving Milestones

- ✓ Successful completion of Study P01
- ✓ Amended agreement with Novo Nordisk
- ✓ European Licensing Agreement with Consilient Health Ltd.

Planned start of CGHD clinical safety and efficacy study (AEZS-130-P02 - multi-national, including U.S.)

Planned submission - FDA and EMA CGHD dossiers

2020	Q1 2021	Q2 2021	July 2022	H2 2022	H1 2023

- ✓ In-licensed NMOSD program from Julius-Maximilians-University
- ✓ In-licensed oral COVID-19 vaccine from Julius-Maximilians-University
- ✓ In-licensed DC-PTH fusion polypeptides from the University of Sheffield

Planned completion of P02 CGHD study according to EMA

Earliest macimorelin CGHD approvals - FDA and EMA

Potential upside by additional pipeline activities